Cannara Biotech Strengthens U.S. Presence and Financial Position
Cannara Biotech Inc. is thrilled to share that it has achieved DTC eligibility for its common shares, making it easier for U.S. investors to purchase and trade its stock. This vital move enhances the company's visibility in the competitive cannabis industry and opens the door to a broader network of brokerage firms.
The Significance of DTC Eligibility
DTC eligibility marks a significant milestone for Cannara as its shares can now be electronically cleared and settled within the U.S. This crucial step not only reduces transaction costs for U.S. investors but also improves the liquidity of Cannara's stock. Zohar Krivorot, the Founder and CEO, highlighted the importance of this achievement, stating it will broaden the company's shareholder base and strengthen its market presence.
Reducing Debt Burdens Through Strategic Moves
In addition to enhancing its marketplace accessibility, Cannara has successfully completed a debt-to-equity conversion, which is a pivotal move that bolsters its financial stability. The company issued 3,462,763 common shares to Olymbec Investments Inc. for approximately $6.2 million in owed debt.
Strengthening the Balance Sheet
This strategic conversion, executed at an issue price of $1.80 per share, primarily includes about $4.7 million in principal and approximately $1.5 million in accrued interest. Nicholas Sosiak, the CFO, expressed that this initiative will help Cannara reduce its leverage and enhance its liquidity while paving the way for future growth initiatives.
Future Potential and Clarifications
Moreover, the company has issued clarifications regarding stock options previously granted for investor relations services. The 40,000 options issued to Bristol Capital Ltd. will now be valid for four years, expiring on April 25, 2029, which ensures that stakeholders remain informed about the company’s commitments.
About Cannara Biotech Inc.
Cannara Biotech Inc. is a vertically integrated producer operating in the cannabis space, focusing on delivering premium-grade products at competitive prices. With two facilities in Quebec spanning over 1,650,000 sq. ft., it is well-positioned to produce approximately 100,000 kg of cannabis annually. This operational scale, combined with Quebec's low electricity costs, allows Cannara to maintain a leading edge in the market.
Frequently Asked Questions
What does DTC eligibility mean for Cannara Biotech?
DTC eligibility allows Cannara's shares to be traded through U.S. brokerage firms, leading to increased liquidity and accessibility for investors in the United States.
How does Cannara plan to use the funds from the debt-to-equity conversion?
The funds will be utilized to strengthen Cannara's balance sheet, reduce debt leverage, and provide liquidity for future growth strategies.
What are Cannara's primary products?
Cannara specializes in premium-grade cannabis products and aims to provide affordable yet quality options within the Canadian market.
What impact does this announcement have on potential investors?
The announcement of DTC eligibility and debt reduction might attract new investors, as it signifies a healthier financial position and greater market liquidity.
Who can I contact for more information about Cannara?
You can contact Nicholas Sosiak, CFO, at nick@cannara.ca or Zohar Krivorot, CEO, at zohar@cannara.ca for any inquiries.
